Differences

This shows you the differences between two versions of the page.

--- home:starting:safety_warnings [10.19.2018] – [Patients' physicians must understand the Marshall Protocol] sallieq
+++ home:starting:safety_warnings [09.14.2022] (current) – external edit 127.0.0.1
@@ Line 66: / Line 66: @@
-===== Immunopathology is dangerous and may be difficult to control =====
+===== Immunopathology could become dangerous and may be difficult to control =====
 <mainarticle> [[home:mp:immunopathology|Immunopathology]] </article>
@@ Line 84: / Line 84: @@
 {{tag>Resources_for_Physicians Starting_the_Marshall_Protocol}}
+<nodisp>
 ===== Notes and comments =====
   * Updated wording, but still think it could be made even better with more work. --Joyful May'13
-  * added "Xarelto increases the risk of bleeding and can cause serious or fatal bleeding. A specific antidote for rivaroxaban is not available. Because of high plasma protein binding, rivaroxaban is not expected to be dialyzable." --Sallie Q May15
-  * altered 3rd line to 'sufficient olmesartan medoxomil (Benicar) to ensure that patient does not run out if there is a delay in delivery or in renewing prescription' --- //Sallie Q 11.02.2016//
-alteration ( @ Patients must understand..) why the use of  telmisartan or azithromycin is considered particularly dangerous  --- //Sallie Q 09.15.2017//
+</nodisp>

home/starting/safety_warnings.txt · Last modified: 09.14.2022 by 127.0.0.1